Market Pulse
Daily · Oct 6, 2026 · data.go.kr + ECOS
KOSPI
6,941.39
-62.35 (-0.89%)
KOSDAQ
919.92
+26.63 (+2.98%)
KOSPI 200
1,095.83
-13.22 (-1.19%)
USD/KRW
1,343.60
214450KOSDAQ·Aug 18, 2026
Diversification benefits set to build
Mirae Asset Securities published a company analysis report on PharmaResearch (214450) titled "Diversification benefits set to build".
Summary
Covers PharmaResearch (214450).
Covered stock
More on 214450
Bottom confirmed; Rejuran remains resilientMirae Asset Securities · May 11, 2026Three key factors to weighMirae Asset Securities · Feb 05, 2026An inevitable valuation resetMirae Asset Securities · Nov 12, 2025Rejuran to remain a staple in aesthetic medicineMirae Asset Securities · Oct 20, 2025Stellar 2Q performance; 2H to be even betterMirae Asset Securities · Aug 12, 2025From regional champion to global contenderMirae Asset Securities · Jul 24, 2025Rejuran��s rapid growth continuesMirae Asset Securities · May 21, 2025Rejuran With Higher Expectations (full ver.)Korea IR Service · Apr 22, 2025Global leader in skin boostersMirae Asset Securities · Feb 11, 2025